BioCentury on BioBusiness,
Tools & Techniques
Making the most of Herception
Tuesday, September 8, 1998
WASHINGTON - Genentech Inc.'s Herceptin stands to become the first approved cancer therapy based on the underlying genetic cause of the disease. But effective use of Herceptin will depend on identifying patients who over-express the HER2 gene and developing a better understanding of the relationship between HER2 expression and the treatment.
Both the treatment and a supporting assay received FDA advisory committee endorsement last week. First, the Oncologic Drugs Advisory Committee (ODAC) endorsed the safety and efficacy of GNE's Herceptin trastuzumab monoclonal antibody for treatment of metastatic breast cancer in women who over-express the HER2 gene (see BioCentury Extra, Sept. 3).
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]